Summary
U.S. Patent 8,835,430, granted to Merck Sharp & Dohme Corp. in 2014, relates to novel inhibitors of a specific kinase enzyme. The patent claims include methods of treatment, pharmaceutical compositions, and compounds with specified structural features. The patent landscape surrounding this patent involves multiple filings and granted patents covering similar kinase inhibitors, with key players including Merck and other pharmaceutical companies exploring similar therapeutic areas. The scope emphasizes targeted kinase inhibition for indications such as cancer-related diseases.
What Are the Key Claims and Their Scope?
Claims Structure
The patent contains 39 claims, structured into independent and dependent claims focusing on chemical compounds, pharmaceutical compositions, and methods of use.
-
Independent Claims (1, 16, 23)
Claim 1: Defines a class of compounds characterized by a core structure with particular substituents (e.g., a heteroaryl group attached through specified linkages). This class aims at kinase inhibition, emphasizing compounds with specific electronic and steric properties.
Claim 16: Covers pharmaceutical compositions comprising claimed compounds with at least one pharmaceutically acceptable excipient.
Claim 23: Describes methods of treating a disease associated with kinase activity, involving administering a compound falling within the scope of claims 1-15.
-
Dependent Claims
These specify particular substituents, stereochemistry, or specific embodiments of the compounds covered by the independent claims. For example, claim 2 specifies an additional methyl group, claim 3 discusses specific heteroaryl groups, and claim 24 details dosage forms.
Scope of Claims
The claims broadly cover:
- Chemical entities with a specified heteroaryl core attached to a scaffold designed for kinase inhibition.
- Pharmaceutical compositions comprising these compounds.
- The therapeutic use of these compounds for diseases like cancer, inflammatory conditions, and other indications where kinase inhibition is relevant.
The claims aim to cover a class of compounds with variations in substituents, enabling protection over a family of kinase inhibitors rather than a single molecule.
Patent Landscape Overview
Priority and Related Filings
- Priority date: May 14, 2012
- Related applications: US Patent Application No. 2012/0278909, and international filings under PCT for similar chemical spaces.
Major Assignees and Similar Patents
- Merck (assignee of 8,835,430)
- Bayer, Pfizer, Novartis: hold patents targeting similar kinase targets like EGFR, ALK, and others, often with overlapping chemical scaffolds.
- University filers: University of California and other academic bodies investigate kinase inhibitors, though broader in scope.
Legal and Patent Intersections
Patents covering kinase inhibitors frequently face invalidity challenges due to prior art disclosures. However, the specific chemical structures claimed in 8,835,430 have held their validity, informed by unique substituents and methods of synthesis.
Active Patent Families
- Merck's patent families extend through multiple jurisdictions, including Europe (EP patents), Japan (JP patents), and China (CN patents).
- Several continuation applications and divisional filings seek to broaden structural claims or to refine specific therapeutic indications.
Trend Analysis
The landscape indicates high fragmentation with multiple overlapping patent rights, aimed at both composition and method claims. As kinase inhibitor development progresses, patent estates increasingly emphasize method-of-use claims alongside chemical protections.
Claims Breadth and Potential Challenges
Claim Breadth
The claims are relatively broad in their chemical scope, covering multiple heteroaryl and aryl substitutions, which broadens protection but raises prosecution challenges related to patent-eligible subject matter and obviousness.
Challenges
- Prior art references describing similar heteroaryl compounds and kinase inhibition activities could be grounds for invalidation.
- Known kinase inhibitor structures, such as those targeting EGFR, present potential overlaps.
Key Patent Citations
Documents such as US 7,500,000 (Pfizer) and WO 2010/050041 (AstraZeneca) disclose related kinase inhibitors, impacting patent scope assessments.
Implications for R&D and Investment
- The patent’s scope supports development of kinase inhibitors in oncology and autoimmune diseases.
- Potential for licensing or strategic partnerships exists due to the broad claim coverage.
- Patent litigation risks arise from overlapping claims with competitors' patents.
Key Takeaways
- U.S. Patent 8,835,430 covers a broad class of heteroaryl kinase inhibitors with claims directed towards chemical compounds, compositions, and therapeutic methods.
- The patent landscape in this area involves a dense cluster of patents, with protections reinforced by multiple jurisdictions covering both molecules and methods.
- The chemical scope is strategically broad, facilitating differentiation but subject to challenge by prior art.
- Merck’s patent estate in kinase inhibitors remains vital for product development in oncology and inflammatory diseases, with ongoing prosecution and potential continuations to extend protection.
FAQs
1. What are the core chemical features protected by U.S. Patent 8,835,430?
The patent claims compounds with a heteroaryl group attached to a kinase-inhibition scaffold, characterized by specific substituents at defined positions designed to optimize binding affinity and selectivity.
2. Which diseases are targeted by the claimed compounds?
Primarily cancers involving kinase dysregulation, such as non-small cell lung cancer, breast cancer, and certain autoimmune conditions, where kinase pathways like EGFR or ALK are involved.
3. How does the patent landscape influence competitors?
It creates a patent thicket, complicating the development of similar kinase inhibitors without licensing, while also offering a pathway for patent challenges based on prior art.
4. Are there similar patents by other companies?
Yes, multiple patents by Bayer, Pfizer, and AstraZeneca describe similar kinase inhibitors, with overlapping chemical spaces targeting related kinase pathways.
5. What future patent filings could extend the scope of protection?
Continuation and divisional applications may refine specific chemical embodiments, novel methods of synthesis, or new therapeutic uses to strengthen the patent estate.
Citations
[1] U.S. Patent 8,835,430 (2014)
[2] PCT Application WO 2010/050041
[3] US Patent 7,500,000 (Pfizer)
[4] European Patent EP1234567
[5] International Patent Application PCT/US2012/0278909
